Relay Therapeutics (RLAY) Competitors $4.07 +0.01 (+0.25%) Closing price 04:00 PM EasternExtended Trading$4.10 +0.03 (+0.74%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. TARS, OGN, ALVO, CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, and HRMYShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Its Competitors Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Tarsus Pharmaceuticals (NASDAQ:TARS) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Do analysts recommend TARS or RLAY? Tarsus Pharmaceuticals presently has a consensus price target of $66.67, suggesting a potential upside of 18.01%. Relay Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 329.98%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Does the media refer more to TARS or RLAY? In the previous week, Relay Therapeutics had 6 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 14 mentions for Relay Therapeutics and 8 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.58 beat Relay Therapeutics' score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Relay Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of TARS or RLAY? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is TARS or RLAY more profitable? Relay Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Tarsus Pharmaceuticals' return on equity of -32.36% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Relay Therapeutics N/A -41.49%-37.43% Which has higher earnings & valuation, TARS or RLAY? Tarsus Pharmaceuticals has higher revenue and earnings than Relay Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M13.03-$115.55M-$2.33-24.24Relay Therapeutics$10.01M70.10-$337.71M-$1.95-2.09 Which has more risk and volatility, TARS or RLAY? Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. SummaryRelay Therapeutics beats Tarsus Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$699.99M$2.91B$5.81B$10.03BDividend YieldN/A46.94%6.67%4.54%P/E RatioN/A23.0075.7526.29Price / Sales70.10531.04449.7481.79Price / CashN/A26.7025.7029.20Price / Book0.885.3411.506.43Net Income-$337.71M$32.95M$3.28B$270.56M7 Day Performance11.20%2.76%1.30%3.01%1 Month Performance26.40%29.32%11.25%9.74%1 Year Performance-57.20%1.14%59.54%26.68% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.7741 of 5 stars$4.07+0.2%$17.50+330.0%-34.9%$699.99M$10.01M0.00330News CoverageTARSTarsus Pharmaceuticals2.244 of 5 stars$58.58+0.7%$66.67+13.8%+86.0%$2.47B$182.95M0.0050Positive NewsOGNOrganon & Co.4.6465 of 5 stars$9.40+2.3%$18.00+91.6%-48.9%$2.45B$6.40B2.674,000News CoveragePositive NewsALVOAlvotech3.0735 of 5 stars$8.07+0.2%$14.00+73.5%-26.4%$2.43B$491.98M18.341,032Short Interest ↑CNTACentessa Pharmaceuticals3.2883 of 5 stars$16.79+1.4%$31.50+87.6%+26.1%$2.25B$6.85M0.00200Positive NewsDNLIDenali Therapeutics4.3818 of 5 stars$15.27-2.4%$33.62+120.1%-38.6%$2.23B$330.53M0.00430News CoveragePositive NewsAnalyst ForecastIBRXImmunityBio2.7137 of 5 stars$2.34+0.4%$10.75+359.4%-28.7%$2.21B$14.74M0.00590Analyst ForecastAGIOAgios Pharmaceuticals4.2812 of 5 stars$37.71-1.2%$56.33+49.4%-15.9%$2.19B$36.50M3.43390News CoverageInsider TradeAnalyst RevisionIDYAIDEAYA Biosciences4.1497 of 5 stars$24.55-1.5%$47.10+91.9%-35.4%$2.15B$7M0.0080Trending NewsAnalyst ForecastOCULOcular Therapeutix3.827 of 5 stars$12.21-2.5%$17.20+40.9%+51.5%$2.12B$63.72M0.00230News CoveragePositive NewsHRMYHarmony Biosciences4.5625 of 5 stars$36.89-2.8%$51.00+38.2%+0.7%$2.12B$714.73M11.90200Positive News Related Companies and Tools Related Companies TARS Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives DNLI Alternatives IBRX Alternatives AGIO Alternatives IDYA Alternatives OCUL Alternatives HRMY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhy This Critical Minerals Explorer Caught Rio Tinto’s EyeAs U.S. defense spending crosses $1 trillion, drones, hypersonics, and next-gen aerospace are taking center st...The Tomorrow Investor | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
